Page 40 - CPG - Clinical Practice Guidelines - Management of Cancer Pain
P. 40

Management of Cancer Pain (Second Edition)

                  5HFRPPHQGDWLRQ
                  •  Patients with persistent cancer pain should be prescribed with regular
                    (around-the-clock) analgesia.
                    {  Opioid  doses  must  be  titrated  to  achieve  optimal  pain  relief  with
                      minimal adverse events.
                    {  Long-acting opioid formulations  may  be considered for  patients
                      once the effective opioid dose has been established.


                         %UHDNWKURXJK SDLQ PDQDJHPHQW

                  ‡  %UHDNWKURXJK SDLQ LQ FDQFHU UHIHUV WR DQ H[DFHUEDWLRQ RI SDLQ LQ WKH
                    setting of chronic pain managed with analgesics around-the-clock. 11
                  •  Breakthrough pain: 41
                    {  typically, is of rapid onset, severe in intensity and self-limiting, with an
                      average duration of 30 min
                    {  affects over 50% of patients with cancer
                    {  PD\ OHDG WR DQ[LHW\  GHSUHVVLRQ  GHFUHDVHG IXQFWLRQLQJ DQG SURORQJHG
                      stays in hospital

                  Every patient on an opioid should have access to  rescue analgesia
                  in order  to  ensure optimal pain  control.  There are two subtypes of
                  breakthrough  pain which are spontaneous  pain and incident  pain.
                  6SRQWDQHRXV  SDLQ  LV  VXGGHQ  DQG  KDV  QR  LGHQWL¿DEOH  WULJJHU   2Q  WKH
                  other hand, incident pain is related to an activity e.g. movement and
                  is  predictable. Incident pain therefore may  be managed by  taking
                                                           41
                  medication prior to the action which precipitates it.  This needs to be
                  differentiated from end-of-dose failure which occurs when medication
                  ZHDUV RII EHIRUH WKH QH[W UHJXODU DQDOJHVLF GRVH LV GXH  (QG RI GRVH
                  IDLOXUH RIWHQ KDSSHQV MXVW SULRU WR WKH QH[W VFKHGXOHG GRVH RI PHGLFDWLRQ
                  and may be attributed to inadequate analgesic doses or dose intervals
                  H[FHHGLQJ WKH PHGLFDWLRQ¶V GXUDWLRQ RI PLQLPXP HIIHFWLYH SODVPD OHYHO
                  for pain control. 42

                  The consensus and standard of care have been on using 5% to 15%
                  (up to 20%) of the morphine equivalent daily dose (MEDD) in the form
                  of an oral IR opioid to manage transient pain episodes. 43, level III  Evidence
                  to establish the appropriate dose of morphine for breakthrough pain is
                  lacking. However, the widely accepted ratio of the rescue dose to the
                  ³DURXQG WKH FORFN´  $7&  PHGLFDWLRQ KDV EHHQ     L H  HTXLYDOHQW WR WKH
                  4-hourly opioid dose. In cases where smaller rescue doses are required
                  e.g. in renal impairment, doses as low as 1/12 of the 24-hour dose can
                  be used. This ‘rescue’ dose may be given as frequently as required (up
                  to hourly). The ATC dose may be adjusted considering the total amount
                  of rescue morphine taken for the last 24 hours. 9; 44, level I


                                             22




          e-cpg inside text-Cancer pain-25/5/24.indd   22               09/08/2024   12:09 AM
   35   36   37   38   39   40   41   42   43   44   45